ArticlePloS one2025
The Ibogaine Experience Scale (IES): Development and psychometric properties of a multidimensional measure of ibogaine's subjective effects.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ibogaine, an indole alkaloid derived from the root bark of Tabernanthe iboga, has long been used in traditional Bwiti healing rituals and shows promise for treating opioid dependence and neurological conditions, but existing psychometric tools fail to capture its distinctive subjective/oneiric (dream-like) effects. To address this gap, we developed the 70-item Ibogaine Experience Scale (IES) through an iterative process informed by a prior qualitative study (n = 20) that identified eight experiential domains. A preliminary 144-item version was completed on site with a mobile device within 48 hours of treatment by 499 participants across two clinical settings-cohort neuropsychiatric treatments (n = 381) and substance use disorder treatments (n = 118). We employed exploratory graph analysis, parallel analysis on polychoric correlations, and iterative item-reduction (Gulliksen's Pool, MIREAL, MSA) to refine the scale. Semi-confirmatory factor analysis used Robust Unweighted Least Squares (RULS) with LOSEFER correction, oblimin rotation, and multiple fit indices (CFI, NNFI, GFI, AGFI, RMSR, WRMR). Cronbach's α, McDonald's ω, H indices, EAP reliability, FDI, ORION, SR, and EPTD assessed internal consistency and factorial quality. The final structure comprises seven factors-Narrative and symbolic visions; Visual changes; Discomfort and challenge; Cosmic/Archetypal Visions; Introspection and personal transformation; Somatosensory hypersensitivity and physiological activation; Dissociation-explaining 53.9% of variance, with excellent fit (CFI = .991; GFI = .983; RMSR = .041; WRMR = .038) and high internal consistency (α = .948; ω = .946; subscale ω = .65-.91). Two subscales exhibited small gender effects. The IES provides a reliable, phenomenologically rich instrument for quantifying ibogaine's distinctive subjective effects. It supports research and clinical assessment by capturing the multidimensional, oneiric/dream-like nature of the ibogaine experience. Future work should confirm this structure in independent, culturally diverse cohorts and explore predictive links between IES domains and therapeutic outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.